Effect of Blocking of @entity32327 @entity36888 on Tumor Angiogenesis and Progression in Normal and Diet-Induced Obese C57BL/6 XXXX .

@entity32327 @entity9842 @entity28 @entity5 @entity19 @entity36888 @entity842 @entity46551 @entity1611 @entity320
BACKGROUND: Obesity is a risk factor for some types of @entity5 . Angiogenesis is a necessary step in the multistage progression of @entity5 such as @entity320 . Previous studies reported that @entity32327 ( @entity32327 ) regulates angiogenesis by activating the @entity36888 on endothelial cells. The present study examined the effects of the @entity36888 antagonist on @entity5 weight, angiogenesis and serum levels of @entity1611 ( @entity1611 ), @entity9842 ( @entity9842 ), and @entity842 (NO). METHODS: Twenty four male C57BL/6 @entity19 were divided into control and @entity28 groups. The control group was fed a normal diet whereas the @entity28 group was fed a high fat diet. After 16 weeks, 2*10(6) @entity19 @entity320 cells were injected subcutaneously into all animals. Half of the control and the @entity28 animals received 1   M, 100   L/kg @entity36888 antagonist ( @entity46551 ) intraperitoneally. After two weeks, the animals were sacrificed, and angiogenic factors and @entity5 weights and angiogenesis were analyzed. RESULTS: Tumor weight in the @entity28 @entity19 was higher than in the control (p<0.05). Treatment with @entity46551 reduced @entity5 weight in the @entity28 animals (p<0.05), without effect on control group (p>0.05). Administration of an @entity36888 antagonist decreased @entity5 angiogenesis (evaluated as capillary density/mm2) and serum @entity1611 concentration in the @entity28 group without altering serum @entity9842 and NO concentrations. CONCLUSIONS: Blockade of the @entity36888 suppressed @entity5 growth in @entity28 @entity19 by affecting @entity5 angiogenesis. Thus, it seems that @entity32327 and its @entity36888 antagonist might be new targets in @entity320 therapy.
